The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Adenosine for Paroxysmal Supraventricular Tachycardia: Dose Ranging and Comparison with Verapamil: Assessment in Placebo-Controlled, Multicenter Trials
Abstract
OBJECTIVE: To assess the safety and efficacy of intravenous adenosine in terminating acute episodes of paroxysmal supraventricular tachycardia. DESIGN: Two prospective, double-blind, randomized, placebo-controlled trials to evaluate dose response in patients receiving adenosine and to compare the effects of adenosine with those of verapamil. PATIENTS: A total of 359 patients with a tachycardia electrocardiographically consistent with paroxysmal supraventricular tachycardia were entered into the two protocols. Patients subsequently found to have arrhythmias other than paroxysmal supraventricular tachycardia were excluded from the efficacy analysis. INTERVENTIONS: The first protocol compared sequential intravenous bolus doses of 3, 6, 9, and 12 mg of adenosine to equal volumes of saline. In the second protocol, patients received either 6 mg and, if necessary, 12 mg of adenosine or 5 mg and, if necessary, 7.5 mg of verapamil. MEASUREMENTS AND MAIN RESULTS: When data are expressed in terms of cumulative response in eligible patients, intravenous adenosine terminated acute episodes of paroxysmal supraventricular tachycardia in 35.2%, 62.3%, 80.2%, and 91.4% of patients who received maximum doses of 3, 6, 9, and 12 mg, respectively, in a four-dose sequence, whereas 8.9%, 10.7%, 14.3%, and 16.1% of patients responded to four sequential placebo doses (P less than 0.0001). In the second trial, cumulative response rates after 6 mg followed, if necessary, by 12 mg of adenosine were 57.4% and 93.4%, and after 5 mg followed, if necessary, by 7.5 mg of verapamil were 81.3% and 91.4%. The average time after injection to termination of tachycardia by adenosine was 30 seconds. Adenosine caused adverse effects in 36% of patients, but they lasted less than 1 minute and were usually mild. CONCLUSIONS: Adenosine in graded doses up to 12 mg rapidly and effectively terminates acute episodes of paroxysmal supraventricular tachycardia in which the atrioventricular node is an integral part of the re-entrant circuit. The overall efficacy of adenosine is similar to that of verapamil, but its onset of action is more rapid. Adverse reactions to adenosine are common but are minor and brief.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the emergency room adenosine IV bolus can terminate AVRT.71,72”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [72]
Citations
Cites
Analysis of Categorical Data by Linear Models
Grizzle, J. E., Starmer, C. F., & Koch, G. G. (1969) · Biometrics · doi:10.2307/2528901 · Cited by 1,504
Drury, A. N., & Szent‐Györgyi, A. (1929) · The Journal of Physiology · doi:10.1113/jphysiol.1929.sp002608 · Cited by 1,493
The cardiac effects of adenosine
Belardinelli, L., Linden, J. M., & Berne, R. M. (1989) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(89)90015-7 · Cited by 772
Lerman, B. B., Belardinelli, L., West, G. A., Berne, R. M., & Dimarco, J. (1986) · Circulation · doi:10.1161/01.cir.74.2.270 · Cited by 473
Dimarco, J., Sellers, T. D., Berne, R. M., West, G. A., & Belardinelli, L. (1983) · Circulation · doi:10.1161/01.cir.68.6.1254 · Cited by 366
Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias
Dimarco, J., Sellers, T. D., Lerman, B. B., Greenberg, M. L., Berne, R. M., & Belardinelli, L. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80181-9 · Cited by 328
Dipyridamole inhibition of adenosine metabolism in human blood
Klabunde, R. E. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90026-2 · Cited by 265
Adenosine and Supraventricular Tachycardia
Camm, A. J., & Garratt, C. J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112053252306 · Cited by 263
Biaggioni, I., Olafsson, B. J., Robertson, R. M., Hollister, A. S., & Robertson, D. (1987) · Circulation Research · doi:10.1161/01.res.61.6.779 · Cited by 209
RANKIN, A. C., Oldroyd, K. G., Chong, E., Rae, A. P., & Cobbe, S. M. (1989) · Heart · doi:10.1136/hrt.62.3.195 · Cited by 161
Research works printed but not linked: 2
- DiMarco J, Cardiac Electrophysiology and Pharmacology of Adenosine and ATP: Basic and Clinical Aspects., 1987, 271
- Sellers T, Cardiac Electrophysiology and Pharmacology of Adenosine and ATP: Basic and Clinical Aspects., 1987, 283
Cited by
Sorted by citations
Items 301–305 of 305
Antiarrhythmika: Medikamentöse Therapie von Herzrhythmusstörungen
Kalusche, D. (2004) · Springer eBooks · doi:10.1007/978-3-642-18649-3_40
Satıcı, M. O., Aksel, G., İslam, M. M., Erdil, F. N., Tarakcıoğlu, D., Eker, N., Küka, B., Gündüz, A. R., Güneş, A., Anıl, M. A., et al. (2026) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-026-04530-9
Paroxysmal Supraventricular Tachycardia Treatment
Villines, T. C., Singh, D. N., Lacharite‐Roberge, A., Hsu, J. L., Rafii, F., & Blood, A. J. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103016
Response limit of standard 6 mg adenosine in paroxysmal supraventricular tachycardia
Akkan, S., Çorbacıoğlu, Ş. K., Ünal, M. Ç., Emektar, E., & Çevik, Y. (2026) · Notfall + Rettungsmedizin · doi:10.1007/s10049-026-01817-3
Adams, R., & Bon (2003) · PubMed Central
Metadata
- Authors
- DiMarco, J. P., Miles, W., Akhtar, M., Milstein, S., Sharma, A. D., Platia, E., McGovern, B., Scheinman, M. M., & Govier, W. C.
- Affiliations
- University of Virginia Medical Center (US)
- The Adenosine for PSVT Study Group
- Corresponding author
- DiMarco, John P.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1990-07-15
- Volume
- 113
- Issue
- 2
- Pages
- 104-110
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2086637755
- Cited by
- 306
- References
- 16
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 4 · 2023: 6 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 7 · 2017: 9 · 2016: 7 · 2015: 9 · 2014: 6 · 2013: 4 · 2012: 5
- FWCI
- 21.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- adenosine, verapamil, intravenous antiarrhythmic therapy, dose-response relationship, tachycardia termination, adverse effects, drug safety and efficacy, calcium channel blockers
- MeSH terms
- Acute Disease, Adenosine, Adult, Aged, Clinical Protocols, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Injections, Intravenous, Male, Middle Aged, Prospective Studies, Tachycardia, Paroxysmal, Tachycardia, Supraventricular, Verapamil, Multicenter Studies as Topic, Confounding Factors, Epidemiologic, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review